EXECUTIVE SUMMARY Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new
Premium Patent Pharmacology Pharmaceutical drug
In the year 2000‚ Merck produced a controversial product called Vioxx. Four years later it gained worldwide attention because of the drug’s potential cardiovascular risks. This was detrimental to the company’s reputation because it was alleged Merck knowingly distributed Vioxx despite its risk. Both Barbara Martinez and Anne W. Mathews of the Wall Street Journal wrote articles into the investigation of Vioxx. Their article suggests Merck knew the dangers of Vioxx at an early stage of its clinical
Premium Clinical trial
Merck & Co.‚ Inc.‚ which is a global health care company that delivers innovative health solutions through its prescription medicines‚ vaccines‚ biologic therapies‚ animal health‚ and consumer care products‚ has a long and rich history of working. There are some main stages of the whole history and background information. In 1851‚ Dr. Emst Christian Friedrich Schering begins developing and selling pharmaceutical products in Berlin. Three years later‚ the company opened its first production facility
Premium Health care Medicine Revenue
Merck is a global research-driven pharmaceutical company dedicated to putting patients first. Merck’s highest priority areas are Alzheimer’s disease‚ atherosclerosis‚ cardiovascular disease‚ diabetes‚ novel vaccines‚ obesity‚ oncology‚ pain and sleep disorders. In addition‚ and importantly for licensing‚ the following other areas remain of high interest for focused investment in new compounds and mechanisms: antibiotics‚ antifungals‚ antivirals (HCV and HIV)‚ asthma‚ COPD‚ neurodegeneration‚ ophthalmology
Premium RNA Protein Immune system
Love The saying ’love makes the world go round’ is accurate‚ in a metaphorical sense. Some people may disagree‚ saying that greed or money makes the world go round‚ but in order to be greedy you have to love something (or at least feel passionately about it) and the most common thing greedy people crave is money‚ even if it is to buy other things. Films are made about it‚ books and songs and poems are written‚ artists draw and paint and sculpt‚ people spend their entire lives waiting for ’The
Free Love
Case Study: Merck Acquisition of Medco Professor Daniel Weiss FI561 January 23‚ 2011 Case Study: Merck Acquisition of Medco Abstract The purpose of this case study is to determine whether it would be beneficial to merge Merck Corporation with Medco Containment Services Incorporated. The merger and acquisition between the world’s largest drug manufacturer and the largest prescription benefits management company (PBM) and marketer of mail order medicines in the United States would result
Premium Mergers and acquisitions Due diligence
3rd‚ 2014 Case 5: Merck‚ the FDA‚ and the Vioxx Recall Section I Merck was one of the world’s leading pharmaceutical firms. The company ranked 4th I sales after Pfizer and Johnson & Johnson and it ranked 5th in assets and market value. Merck ranked 1st in profits‚ earning $7.33 billion on $30.78 billion in sales. In 2006‚ Merck faced major challenges with their once best selling prescription painkillers‚ Vioxx which was pulled off the market in September of 2004 after Merck learned it increased
Free Pharmacology Food and Drug Administration
patent. In 1995‚ Merck entered into a licensed agreement and collaboration to hold the rights to market Gardisil in all countries accept Australia and New Zealand. Merck was invested heavily in Gardasil‚ spending $1.2 billion in fifteen years before seeking approval from the FDA. After results of all phase trials were impressive‚ Merck moved for FDA approval. Merck hoped to receive approval before a competitive drug‚ known as Cervarix was approved. If so‚ it would guarantee Mercks first mover advantage
Premium Human papillomavirus HPV vaccine Cervical cancer
Emotion –induced blindness Introduction Emotional visual scenes are powerful attracters of attention. Evidence suggests that emotional stimuli themselves attract attention‚ and they can disrupt perception of subsequent stimuli (Anderson and Phelps‚ 2001). In a visual attention search task‚ faster reaction time has been found when target is an emotional stimulus than neutral stimuli (Ohman‚ Lundqvist‚ & Esteves‚ 2001). From these result it seems that emotional stimuli enhance perception of such
Premium Psychology Attention Working memory
Merck‚ the FDA‚ and the VIOXX Recall MBA 520 Ethics and Leadership in a Global Environment 11.15.2009 MBA 520 15 November 2009 Merck‚ the FDA‚ and the VIOXX Recall In 1999‚ Merck started a clinical trial called VIGOR‚ checking the effectiveness of VIOXX in patients with gastrointestinal problems‚ and in this trial they noted for the first time that patients taking VIOXX suffered roughly twice as many heart attacks and strokes as those taking the control‚ Naproxen.
Premium Social responsibility Clinical trial Corporate social responsibility